The Kratom Civil War Is Heating Up, and MAHA Has Picked a Side
The kratom industry's struggle for legitimacy is a symptom of a broader trend in the tech and health sectors: the increasing scrutiny of substances that intersect with opioid effects and digital commerce. The convergence of these factors creates a perfect storm of regulatory pressure, with policymakers and health advocates pushing to contain the risks associated with substances like kratom and 7-OH. This high-stakes battle has significant implications for the future of digital health and wellness, as the lines between traditional health products and digital marketplaces continue to blur.
The kratom industry's fate will be a key test case for the regulatory landscape of digital health and wellness products. As the 7-OH ban debate heats up, kratom proponents will need to navigate a complex web of regulatory hurdles and public perception challenges to preserve their market share. Meanwhile, RFK Jr.'s efforts to ban 7-OH may set a precedent for similar regulatory actions against other substances with opioid-like effects.
About the Source
This analysis is based on reporting by Wired. Here is a short excerpt for context:
Both kratom and one of its active components, 7-OH, have opioid-like effects and are widely available across the US. As health secretary RFK Jr. aims to get 7-OH banned, proponents of both are fighting.Read the original at Wired
